원발성 중추신경계 림프종(PCNSL) 시장

This reports provides a data-driven overview of the current and future competitive landscape in Primary CNS Lymphoma Therapeutics.

• In 2024 and 2029, Urban China is anticipated to have the highest number of diagnosed prevalent cases of PCNSL, representing a large proportion of global cases.
• Currently, PCNSL treatment relies mostly on off-label agents, and the Bruton's tyrosine kinase (BTK) inhibitors currently available to treat refractory/relapsed (r/r) PCNSL cases.
• The PCNSL pipeline holds 43 molecules, with no assets in the pre-registration stage, one asset in Phase III development, and another 23 in Phase II.
• Over the past decade, 171 clinical trials have been conducted in PCNSL. The year with the most studies initiated was 2021 (26 trials) followed by 2020 (24 trials).
• During the past 20 months, six mergers and acquisitions and 11 strategic alliances involving companies developing PCNSL assets were completed globally.
• There remains a significant unmet need, which is driving pipeline development of BTK inhibitors and novel cell therapies to improve outcomes.

Scope

GlobalData's Primary CNS Lymphoma: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Primary CNS Lymphoma Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Primary CNS Lymphoma Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profile and Sales Forecast

5 Pricing and Reimbursement Assessment

6 Pipeline Drugs Assessment

• 6.1 Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Product Profile and Sales Forecast
• 6.6 Drug-specific PTSR and LoA
• 6.7 Indication-specific and Therapy Area-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Top 20 Biomarkers by Trial Phase
• 7.7 Overview of Trials by Geography
• 7.8 Single-Country and Multinational Trials by Region
• 7.9 Top 20 Sponsors with Breakdown by Phase
• 7.10 Top 20 Sponsors with Breakdown by Status
• 7.11 Overview by Endpoint Status
• 7.12 Overview by Race and Ethnicity
• 7.13 Enrollment Data
• 7.14 Top 20 countries for Trial Sites
• 7.15 Top 20 Sites Globally
• 7.16 Feasibility Analysis - Geographic Overview
• 7.17 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer